Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ominsky

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Bone|August 12, 2015
Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact ratsMichael S Ominsky, Danielle L Brown, Gwyneth Van, et al.
Endocrinology|September 27, 2014
Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibodyXiaodong Li, Qing-Tian Niu, Kelly S Warmington, et al.
Bone|June 23, 2009
Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerinXiaodong Li, Michael S Ominsky, Marina Stolina, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 4, 2026
Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward TrialMishaela R Rubin, Bart L Clarke, Lorenz C Hofbauer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 20, 2010
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male ratsXiaodong Li, Kelly S Warmington, Qing-Tian Niu, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 25, 2008
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized ratsMichael S Ominsky, Xiaodong Li, Frank J Asuncion, et al.
Bone|September 5, 2017
Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidismXiaodong Li, Longchuan Yu, Frank Asuncion, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2009
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strengthMichael S Ominsky, Marina Stolina, Xiaodong Li, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 10, 2010
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studiesIan R Reid, Paul D Miller, Jacques P Brown, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 10, 2016
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ AgonistsXiaodong Li, Shanaka Stanislaus, Frank Asuncion, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Bone|August 12, 2015
Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact ratsMichael S Ominsky, Danielle L Brown, Gwyneth Van, et al.
Endocrinology|September 27, 2014
Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibodyXiaodong Li, Qing-Tian Niu, Kelly S Warmington, et al.
Bone|June 23, 2009
Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerinXiaodong Li, Michael S Ominsky, Marina Stolina, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 4, 2026
Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward TrialMishaela R Rubin, Bart L Clarke, Lorenz C Hofbauer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 20, 2010
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male ratsXiaodong Li, Kelly S Warmington, Qing-Tian Niu, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 25, 2008
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized ratsMichael S Ominsky, Xiaodong Li, Frank J Asuncion, et al.
Bone|September 5, 2017
Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidismXiaodong Li, Longchuan Yu, Frank Asuncion, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2009
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strengthMichael S Ominsky, Marina Stolina, Xiaodong Li, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 10, 2010
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studiesIan R Reid, Paul D Miller, Jacques P Brown, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 10, 2016
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ AgonistsXiaodong Li, Shanaka Stanislaus, Frank Asuncion, et al.
Pageof 9